All News

Michael Hegener, PharmD, BCACP, discusses how workforce development can best address the evolving knowledge, skills, and abilities needed in community pharmacy practice.

Researchers evaluated PBM reimbursement practices in Medicare and whether they resulted in out-of-pocket cost increases for Part D beneficiaries.

Micah Cost, PharmD, MS, CAE, discusses the biggest issues currently impacting the pharmacy profession.

Kaitlin Bates, PharmD, discusses the results of implementing a program used to support standardized pharmacy quality measures.

Researchers conducted a scoping review to evaluate conversational AI agents and their use in pharmacy education.

This designation follows Hadlima’s low-concentration prefilled syringes and single-dose vials, which were designated in June 2024.

Pharmacists play a critical role in vaccination and education for patients about the evolving infectious disease landscape.

Researchers aimed to estimate the impact of using behavioral science principles within communication intended for hypertension medication adherence.

Ustekinumab is a medication used to treat and manage inflammatory conditions, including psoriasis, psoriatic arthritis, and inflammatory bowel disease.

Researchers explored how relationships between physicians, pharmacists, and patients are associated with the use of generic drugs in Japanese pharmacies.

Mitchell Barnett, PharmD, MS, discusses what lessons can be learned from a community pharmacy drug disposal program.

David Swenson, RPh, discussed drug shortage technology that his company is helping bring to community pharmacies across the country.

By protecting pregnant patients from cardiometabolic risk factors, healthier blood pressure can be promoted for children.

PBM expert Antonio Ciaccia, president of 3 Axis Advisors and CEO of 46brooklyn Research, discussed recent events in the pharmacy benefits industry and how it is moving toward PBM reform.

Antonio Ciaccia, President of 3 Axis Advisors, CEO of 46brooklyn Research, and pharmacy benefits expert, discussed his role in uncovering PBM practices and pharmacy consulting.

Triptans are often a first-line treatment for migraine and can be used to treat menstrual migraine and cluster headaches.

A conversation with Razanne Oueini, PharmD, MSc, CPHQ, senior manager of Performance Measurement at PQA, at PQA 2025.

Researchers explored the current evidence regarding women’s reactions to biological therapies for treating atopic dermatitis during pregnancy.

Acetaminophen exposure can increase the risk of perforation, ulceration, bleeding, heart failure, hypertension, and chronic kidney disease.

David Swenson, RPh, Founder and CEO of ShortStop Rx, joined Drug Topics to discuss the CCT Rx Shortage Solutions technology and how it’s helping combat drug shortages in the US.

Adalimumab-aaty (Yuflyma) prefilled syringes and autoinjectors are now fully interchangeable with the reference product adalimumab (Humira) across marketed dosage forms and strengths.

The supplemental new drug application for roflumilast (Zoryve) is approved for adult and pediatric patients 12 years and older.

Approval comes from positive results in the MATINEE and METREX phase III trials, with data showing a significant reduction in annual rates of COPD exacerbations among patients.

Insulin delivery technology company Sequel Med Tech announced its future partnership with Abbott’s glucose-ketone sensor, which is currently under development.

A conversation with Micah Cost, PharmD, MS, CAE, CEO of PQA, at PQA 2025.

During Viral Hepatitis Awareness Month, Jeff Goad, PharmD, MPH, joined Over the Counter to discuss hepatitis vaccines and the common trends pharmacists in this space should keep in mind.

The new program aims to reduce costs for patients, with savings estimated at as much as $3600 per year.

Through a comprehensive review and meta-analysis, researchers identified the correlation between atopic dermatitis and dementia.